Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Target Therapy with FOLFIRINOX in Advanced Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
NCT03768375Phase 2Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Nov 2016
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, trastuzumab, gefitinib, lapatinib, everolimus in extrahepatic cholangiocarcinoma (eCCA), gallbladder carcinoma, sponsored by Shanghai Jiao Tong University School of Medicine. Status: unknown.
02
Drugs
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT03768375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768375.